GlassScriptPhysician profile
Geetha Priyanka
NPI 1639241862
$8,396.97
in general payments reported to CMS, 2019-2025
58 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $385 · 2021: $1,041 · 2022: $2,589 · 2023: $1,485 · 2024: $456 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,232.66 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $920.20 | 2022 | |
| Abbvie INC. | $811.43 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $515.20 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $508.90 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $386.65 | 2019-2025 | |
| Amgen INC. | $377.91 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $348.62 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $338.95 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $313.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $310.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $245.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $229.43 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $190.12 | 2021-2022 | |
| Exact Sciences Corporation | $188.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $187.61 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Priyanka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.